Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec and Abbott have reported the additional results from the Select Phase 2b trial, which assessed the investigational compound daclizumab high-yield process (DAC HYP) to treat relapsing-remitting multiple sclerosis (RRMS).
Subscribe to our email newsletter
DAC HYP, a humanized monoclonal antibody, is subcutaneous formulation of daclizumab which binds to CD25, a receptor subunit that is expressed at high levels on T cells that are abnormally activated in autoimmune conditions like MS.
Select, a phase 2b global, randomized, double-blind, placebo-controlled, one-year, dose-ranging study, comprising 600 patients, evaluated two doses of DAC HYP, 150 mg or 300 mg every four weeks.
The study met the primary endpoint which was the reduction in annualized relapse rate in patients with RRMS at one year.
The secondary endpoints were reduction in the cumulative number of new Gd+ lesions between weeks eight and 24.